Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
暂无分享,去创建一个
R. Greil | S. Park | E. Antonarakis | G. Kramer | M. D. De Santis | Jeri Kim | E. Yu | M. Retz | M. Sumitomo | N. Mehra | P. Fong | C. Poehlein | E. Rosenbaum | S. Begbie | Yi-Hsiu Huang | K. Chiu | J. Goh | M. Kolinsky | Jinchun Zhang | Núria Sala-González | Hiroyoshi Suzuki | R. Gafanov | F. Massari | P. Qiu | Jae Lyun Lee | P. Yanez | F. Rey | J. P. Sade | R. McDermott | S. Shin | G. Roubaud
[1] N. Clarke,et al. Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). , 2023, Journal of Clinical Oncology.
[2] A. Tafreshi,et al. Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. , 2022, European urology.
[3] A. Armstrong,et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2022, NEJM evidence.
[4] Thomas D. Wu,et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses , 2022, Immunity.
[5] Giuseppe Caruso,et al. Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis , 2021, Journal of personalized medicine.
[6] A. Jimeno,et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] A. Tafreshi,et al. 612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients , 2021, Annals of Oncology.
[8] Wei Zhang,et al. Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer. , 2021, Pharmacological research.
[9] E. Antonarakis,et al. Targeting the spectrum of immune checkpoints in prostate cancer , 2021, Expert review of clinical pharmacology.
[10] K. Rahbar,et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. , 2021, The New England journal of medicine.
[11] K. Mortezaee,et al. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. , 2021, Clinical immunology.
[12] C. Parker,et al. Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] F. Saad,et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[14] F. Saad,et al. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. , 2020, Clinical genitourinary cancer.
[15] C. Drake,et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Carles,et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.
[17] G. Mills,et al. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. , 2018, Cancer research.
[18] C. Ager,et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy , 2018, The Journal of clinical investigation.
[19] A. Chinnaiyan,et al. Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. , 2018, The American journal of pathology.
[20] R. DePinho,et al. Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer , 2017, Nature.
[21] G. Hortobagyi,et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.
[22] S. Granjeaud,et al. Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. , 2016, Cancer research.
[23] G. Kristiansen,et al. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer , 2015, Clinical Cancer Research.
[24] V. Kuchroo,et al. TIGIT predominantly regulates the immune response via regulatory T cells. , 2015, The Journal of clinical investigation.
[25] A. Zoubeidi,et al. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer , 2014, Oncotarget.
[26] Frank Bretz,et al. Multiple and Repeated Testing of Primary, Coprimary, and Secondary Hypotheses , 2011 .
[27] W. Isaacs,et al. Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing , 2008, Clinical Cancer Research.
[28] L. Tanoue,et al. The National Comprehensive Cancer Network , 1998, Cancer.
[29] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[30] A. D'Amico,et al. NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.